Objective To analyze the changes of antibody levels in positive patients with epidemic hemorrhagic fever(EHF) in Dongwan, and to provide effective theoretical guidance for the prevention . Methods From January 2018 to April 2022, the antibody test and general sociological characteristics, such as age, sex, occupation of 153 patients who were confirmed to be positive for serum EHF antibody by establishing infectious disease report cards were collected. Statistical analysis was performed using t test and 2test. Results Among of 153 patients , 70 were IgG positive, and the antibody positive rate was 45.75%. There was no significant difference in IgG antibody positive rate between EHF patients of different gender（χ²=0.165，P=0.685）. Commercial services (76.90%), workers (34.10%), unemployed or retired (44.10%) had the highest antibody positive rate. The IgG positive rate of EHF patients in different age groups was different. The antibody positive rate was the highest in the age group of 25-35 years old, and the antibody positive rate was lower in the age group of 60 years old and later. Among the 153 patients, the IgG antibody positive rate of the patients with onset in December, January and February was the highest, reaching 60.71% and 66.67% respectively. The IgG antibody positive rate of the patients with onset in April September was lower（ χ²=14.366，P=0.021）. Conclusion The positive rate of IgG antibody in EHF patients in Dongguan was high, which was related to occupation, age and time of onset; It is necessary to strengthen vaccination for this group of people to improve the antibody immunity level.

Immune checkpoint inhibitors are able to reactivate the immune system therefore enhance the anti-tumor effects. However, over-activated T cells may induce immune related adverse events (irAEs). Hematological irAEs are rarely reported, which mainly represent as mono-lineage cytopenia or pancytopenia, including autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), neutropenia and aplastic anemia, sometimes even lethal, such as hemophagocytic lymphohistiocytosis. The clinical manifestations of hematological irAEs will be summarized and recommendations of diagnosis and treatment are proposed.